Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The early and late results of 6 months' chemotherapy (2/INH, RMP, PZA and 4/INH, RMP) of newly detected, bacteriologically positive pulmonary tuberculosis are presented. In the initial period during hospitalisation in nonselected 290 patients 100% conversion of sputum was obtained while in the continuous out-patients' treatment 1.3% of patients were again found to have sputum positive for acid fast bacilli. Toxic reactions on drugs were found in 5.8% of patients: in 3.4% the hepatitis developed yet in all in mild course. The narrowing of medical contraindications for 6 months' regimen is suggested especially in chronic alcoholics since in 15.2% of them the therapy with 9 months' regimen had to be introduced (INH, RMP, EMB/SM). In more than 2 yrs' follow up after the end of chemotherapy in 2.4% of patients--mostly noncooperative alcoholics--the recidivation was found already a few months after discontinuation of the therapy. The problem of chronic alcoholics and noncooperative patients for short course chemotherapy is discussed. The special measures are suggested: obligatory hospitalisation during initial therapy, supervising chemotherapy in out-patients' departments as well as intermittent regimen and prolongation of 6 months' therapy.
 ...
PMID:[Clinical study of a 6-month chemotherapy regimen in the treatment of pulmonary tuberculosis. Results approximately 2 years after completion of chemotherapy]. 279 72

In Guadeloupe, from January 1980 to December 1984, 420 leprosy patients were put under daily multidrug therapy: 10 mg/kg RMP plus 100 mg DDS during six months for paucibacillary patients, 10 mg/kg RMP plus 100 mg DDS during 24 months supplemented during the 12 first months with 10 mg/kg of a thioamide, ethionamide or protionamide, for multibacillary patients. The approval to the treatment was satisfactory in all the patients with active leprosy, new cases and relapse cases, less in the inactive patients already treated with dapsone only. The patients's compliance to treatment was satisfactory too. The lepra reactions were observed with a 19% frequency which is not different of the 15% frequency of lepra reactions observed in patients treated with DDS only. Hepatitis were observed only in multibacillary patients treated with PTH and RMP with a 14% frequency. Discontinuing treatment with RMP and PTH but not DDS resulted in recovery. When RMP was resumed without PTH, the hepatitis did not recur. All patients responded favorably under multidrug therapy and no relapse was observed among the 45 paucibacillary patients after a four year-surveillance and among the 16 multibacillary patients after a three year-surveillance.
 ...
PMID:[5-year assessment of daily multi-drug therapy of leprosy in Guadeloupe since 1980]. 329 12

The authors have studied tolerance of multibacillary patients to 4 MDT regimens. These 4 regimens consist of: One supervised part in which RMP-ETH combination in once-monthly administered; furthermore, in 2 of these regimens, is included one "starter phase" with daily doses of that combination for 2 months. One self-administered part during which CLO is associated either to DDS for new cases, or to ETH for relapses. Clinical Supervision: Out to 310 multibacillary patients, 7 cases of hepatitis with or without icterus, but no death due to the treatment. Interruptions of MDT have been temporary and have been observed in 0.9 to 5.6% of the patients according to the therapeutic regimen. Checking SGOT: The SGOT were abnormally high in 16.3% of the patients before treatment. These pre-existing liver damages do not favour the appearance of intolerance disorders. During MDT, abnormal increases in SGOT are observed in 27% of the patients but there is no exact correlation between the absorbed doses of ETH and the frequency in SGOT increases. The clinical or biological evidence of liver damages occur rather early (1st, 2nd month) in regimens with "starter phase", and later (4th-8th month) in those without "starter phase". But introduction of "Starter phase" does not increase the global frequency of such intolerance accidents. ETH combined with RMP, must be used under steady clinical and biological supervision. Recalling the results of a previous survey, the authors consider that a long duration of MDT is not necessary. For the multibacillary leprosy treatment, they propose a diphasic regimen, more easily applicable in the field than the WHO protocols. In this diphasic regimen, the only part which must be supervised is the initial "starter phase" of 2 month. It consists of daily administration of 3 antibacillary drug among which RMP and ETH. The second phase is a relay treatment using 2 drugs, CLO combined with DDS or ETH, self-administered until smear negativity.
 ...
PMID:[Multi-drug therapy trials for leprosy in Senegal: first observations relative to liver tolerance of multibacillary patients. Therapeutic consequences]. 329 13